Скачать с ютуб Investigating RP1 in high-risk melanoma in the IGNYTE trial в хорошем качестве

Investigating RP1 in high-risk melanoma in the IGNYTE trial

Yana Najjar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, comments on the IGNYTE study (NCT03767348) of the oncolytic virus vusolimogene oderparepvec (RP1) and its ongoing assessment in for immunotherapy-refractory melanoma. RP1 has a novel use in stage 2B/C melanoma to potentially reduce nodal metastasis pre-surgery, and the trial enrolled patients received three RP1 injections into the tumor bed, with effects on nodal and tumor microenvironments assessed through extensive tissue analysis and immune profiling. Findings will compare sentinel metastasis rates against historical controls, informing future therapeutic applications. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.